These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 37157906)

  • 21. Phase II trial of co-administration of CD19- and CD20-targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma.
    Sang W; Shi M; Yang J; Cao J; Xu L; Yan D; Yao M; Liu H; Li W; Zhang B; Sun K; Song X; Sun C; Jiao J; Qin Y; Sang T; Ma Y; Wu M; Gao X; Cheng H; Yan Z; Li D; Sun H; Zhu F; Wang Y; Zeng L; Li Z; Zheng J; Xu K
    Cancer Med; 2020 Aug; 9(16):5827-5838. PubMed ID: 32608579
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Co-expression of PD-L1 and p-AKT is associated with poor prognosis in diffuse large B-cell lymphoma via PD-1/PD-L1 axis activating intracellular AKT/mTOR pathway in tumor cells.
    Dong L; Lv H; Li W; Song Z; Li L; Zhou S; Qiu L; Qian Z; Liu X; Feng L; Meng B; Fu K; Wang X; Pan-Hammarström Q; Wang P; Wang X; Zhang H
    Oncotarget; 2016 May; 7(22):33350-62. PubMed ID: 27147575
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Decitabine combined with RDHAP regimen in relapsed/refractory diffuse large B cell lymphoma.
    Kong X; Zhang X; Ding M; Feng X; Dong M; Zhang L; Fu X; Li L; Li X; Sun Z; Yan J; Wang X; Wu X; Chen Q; Zhang M; Zhu L
    Cancer Med; 2023 Apr; 12(7):8134-8143. PubMed ID: 36695162
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chidamide with PEL regimen (prednisone, etoposide, lenalidomide) for elderly or frail patients with relapsed/refractory diffuse large B-Cell lymphoma -results of a single center, retrospective cohort in China.
    Wang Y; Xue H; Song W; Xiao S; Jing F; Dong T; Wang L
    Hematol Oncol; 2022 Oct; 40(4):617-625. PubMed ID: 35165928
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tafasitamab Plus Lenalidomide Versus 3 Rituximab-Based Treatments for Non-Transplant Eligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Matching-Adjusted Indirect Comparison.
    Cordoba R; Prawitz T; Westley T; Sharma A; Ambarkhane S; Kapetanakis V; Sabatelli L
    Adv Ther; 2022 Jun; 39(6):2668-2687. PubMed ID: 35403948
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety and efficacy of PD-1 and PD-L1 inhibitors in relapsed and refractory Hodgkin's lymphoma: a systematic review and meta-analysis of 20 prospective studies.
    Sun C; Chen H; Wang Y; Zheng C
    Hematology; 2023 Dec; 28(1):2181749. PubMed ID: 36892260
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immune evasion-related extranodal large B-cell lymphoma: A report of six patients with neoplastic PD-L1-positive extranodal diffuse large B-cell lymphoma.
    Suzuki Y; Sakakibara A; Shimada K; Shimada S; Ishikawa E; Nakamura S; Kato S; Takahara T; Asano N; Satou A; Kohno K
    Pathol Int; 2019 Jan; 69(1):13-20. PubMed ID: 30601579
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Expression of programmed cell death 1/programmed cell death ligand 1 in the tumor microenvironments of primary gastrointestinal diffuse large B cell lymphomas.
    Liu Y; Ma J; Yu K; Li M; Liu F; Yan Q; Wang Z; Guo S
    Pathol Res Pract; 2018 Apr; 214(4):507-512. PubMed ID: 29598887
    [TBL] [Abstract][Full Text] [Related]  

  • 29. KEYNOTE-025: Phase 1b study of pembrolizumab in Japanese patients with previously treated programmed death ligand 1-positive advanced non-small-cell lung cancer.
    Nishio M; Takahashi T; Yoshioka H; Nakagawa K; Fukuhara T; Yamada K; Ichiki M; Tanaka H; Seto T; Sakai H; Kasahara K; Satouchi M; Han SR; Noguchi K; Shimamoto T; Kato T
    Cancer Sci; 2019 Mar; 110(3):1012-1020. PubMed ID: 30618179
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Outcomes of polatuzumab vedotin-containing regimens in real-world setting of relapsed and or refractory diffuse large B-cell lymphoma patients: a matched-control analysis from the Thai Lymphoma Study Group (TLSG).
    Rattanathammethee T; Norasetthada L; Bunworasate U; Wudhikarn K; Julamanee J; Noiperm P; Lanamtieng T; Phiphitaporn P; Navinpipat M; Kanya P; Jit-Ueakul D; Wongkhantee S; Suwannathen T; Chaloemwong J; Wong P; Makruasi N; Khuhapinant A; Prayongratana K; Niparuck P; Kanitsap N; Suwanban T; Intragumtornchai T
    Ann Hematol; 2023 Jul; 102(7):1887-1895. PubMed ID: 37202499
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Programmed death ligand 1 expression in diffuse large B cell lymphoma: correlation with clinicopathological prognostic factors.
    Ibrahim EM; Refat S; El-Ashwah S; Fahmi MW; Ibrahiem AT
    J Egypt Natl Canc Inst; 2023 May; 35(1):12. PubMed ID: 37150782
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The expression and clinical significance of programmed cell death receptor 1 and its ligand in tumor tissues of patients with extranodal nasal NK/T cell lymphoma.
    Feng Y; Feng X; Jing C; Yu X; Zheng Y; Xu C
    Sci Rep; 2022 Jan; 12(1):36. PubMed ID: 34996890
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic and clinicopathological significance of PD-1/PD-L1 expression in the tumor microenvironment and neoplastic cells for lymphoma.
    Xie M; Huang X; Ye X; Qian W
    Int Immunopharmacol; 2019 Dec; 77():105999. PubMed ID: 31704289
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of pembrolizumab for patients with previously treated advanced vulvar squamous cell carcinoma: Results from the phase 2 KEYNOTE-158 study.
    Shapira-Frommer R; Mileshkin L; Manzyuk L; Penel N; Burge M; Piha-Paul SA; Girda E; Lopez Martin JA; van Dongen MGJ; Italiano A; Xu L; Jin F; Norwood K; Ott PA
    Gynecol Oncol; 2022 Aug; 166(2):211-218. PubMed ID: 35361487
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Outcomes of relapsed/refractory diffuse large B-cell lymphoma and influence of chimaeric antigen receptor T trial eligibility criteria in second line-A population-based study of 736 patients.
    Harrysson S; Eloranta S; Ekberg S; Enblad G; El-Galaly TC; Sander B; Sonnevi K; Andersson PO; Jerkeman M; Smedby KE
    Br J Haematol; 2022 Jul; 198(2):267-277. PubMed ID: 35468219
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Differential Efficacy of Pembrolizumab According to Metastatic Sites in Patients With PD-L1 Strongly Positive (TPS ≥ 50%) NSCLC.
    Takeyasu Y; Yoshida T; Shibaki R; Matsumoto Y; Goto Y; Kanda S; Horinouchi H; Yamamoto N; Motoi N; Ohe Y
    Clin Lung Cancer; 2021 Mar; 22(2):127-133.e3. PubMed ID: 33183972
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lenalidomide plus R-GDP (R2-GDP) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Final Results of the R2-GDP-GOTEL Trial and Immune Biomarker Subanalysis.
    Palazón-Carrión N; Martín García-Sancho A; Nogales-Fernández E; Jiménez-Cortegana C; Carnicero-González F; Ríos-Herranz E; de la Cruz-Vicente F; Rodríguez-García G; Fernández-Álvarez R; Martínez-Banaclocha N; Gumà-Padrò J; Gómez-Codina J; Salar-Silvestre A; Rodríguez-Abreu D; Gálvez-Carvajal L; Labrador J; Guirado-Risueño M; García-Domínguez DJ; Hontecillas-Prieto L; Espejo-García P; Fernández-Román I; Provencio-Pulla M; Sánchez-Beato M; Navarro M; Marylene L; Álvaro-Naranjo T; Casanova-Espinosa M; Sánchez-Margalet V; Rueda-Domínguez A; de la Cruz-Merino L
    Clin Cancer Res; 2022 Sep; 28(17):3658-3668. PubMed ID: 35727601
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The expression and clinical relevance of PD-1, PD-L1, and TP63 in patients with diffuse large B-cell lymphoma.
    Fang X; Xiu B; Yang Z; Qiu W; Zhang L; Zhang S; Wu Y; Zhu X; Chen X; Xie S; Yi X; Liang A; Zeng Y
    Medicine (Baltimore); 2017 Apr; 96(15):e6398. PubMed ID: 28403071
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PD-L1 expression is associated with the spontaneous regression of patients with methotrexate-associated lymphoproliferative disorders.
    Gion Y; Doi M; Nishimura Y; Ikeda T; Filiz Nishimura M; Sakamoto M; Egusa Y; Nishikori A; Fujita A; Iwaki N; Nakamura N; Yoshino T; Sato Y
    Cancer Med; 2022 Jan; 11(2):417-432. PubMed ID: 34842351
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PD-L1 (SP142) expression in neoplastic cells predicts a poor prognosis for patients with intravascular large B-cell lymphoma treated with rituximab-based multi-agent chemotherapy.
    Suzuki Y; Kohno K; Matsue K; Sakakibara A; Ishikawa E; Shimada S; Shimada K; Mabuchi S; Takahara T; Kato S; Nakamura S; Satou A
    Cancer Med; 2020 Jul; 9(13):4768-4776. PubMed ID: 32367674
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.